Clinical trials: Atheromatosis
Hyperlipidemia, Metabolic Syndrome X
Low Fat Plant-Based Supplemented Diet Effects on Risk Factors for Chronic Non-communicable Diseases
The effect of a diet free from animal-sourced nutrients on a variety of risk factors for chronic non-communicable diseases in weight reduction programs is not well established.
- Trial name
- LFPBDS2 (NCT02905448)
- Testing
- Low fat plant-based nutrition
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Barbara Jakše s.p.
High Risk Atherosclerotic Cardiovascular Disease
Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)
This study is designed to evaluate the efficacy of automated electronic alerts in the electronic health record to improve rates of best practices in the treatment of patients with hyperlipidemia who present in the setting of…
- Trial name
- NCT04394715
- Testing
- Electronic Alert
- Where
- 4 sites in United States
- Volunteers
- 2,596 people
- Sponsor
- Yale University
Peripheral Vascular Diseases
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
The particular aim of this study is the comparison of the diagnostic results of MRA images upon application of Vasovist (gadofosveset), a contrast agent not yet available on the market, with the MRA images upon application of a…
- Trial name
- NCT00296855
- Testing
- Vasovist (BAY86-5283, MS-325)
- Where
- 26 sites in Argentina, Austria and 4 more
- Volunteers
- 261 people
- Sponsor
- Bayer
Cardiovascular Diseases, Heart Diseases
Reanalysis of CVD Risk Factors Via Likelihood Methods
To reanalyze data on risk factors for cardiovascular disease (CVD) including total cholesterol and high density lipoprotein (HDL) cholesterol for the subjects in the first, second, and third exams of the NHLBI Twin Study.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis
- Trial name
- NCT00005408
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
- Conditions
- Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease
- Trial name
- NCT04007055
- Testing
- Point of care screening for HPR, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Marissa Jarosinski
Stenosis of Artery, Peripheral Arterial Disease
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
This is a prospective, single-center, non-randomized phase 2, first-in-iliac artery study, to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of peripheral arterial occlusive disease in…
- Conditions
- Stenosis of Artery, Peripheral Arterial Disease, Iliac Artery Disease, Iliac Artery Occlusion
- Trial name
- NCT03994185
- Testing
- Placement of WRAPSODY stent graft
- Sponsor
- Merit Medical Systems, Inc.
Arterial Occlusive Diseases, Atherosclerosis
A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries
The REGAL study is a European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing additional data including health economics data to support the use of the ELUVIA stent in the treatment of lesions…
- Conditions
- Arterial Occlusive Diseases, Atherosclerosis, Vascular Diseases, Arteriosclerosis
- Trial name
- REGAL (NCT03037411)
- Testing
- Peripheral stenting
- Where
- 23 sites in Austria, Belgium and 3 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
HIV Infection, Cardiovascular Diseases (CVD)
Colchicine to Reduce Coronary Artery Inflammation in People With HIV
The purpose of this study is to evaluate whether colchicine can reduce coronary artery inflammation in people living with HIV and high cardiovascular risk.
- Trial name
- COLCOHIV (NCT07704164)
- Testing
- Colchicine 0.5 mg
- Where
- 4 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Coronary Artery Disease (CAD), Peripheral Arterial Disease
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary…
- Trial name
- NCT07318155
- Testing
- SRSD107, 0.9 % sodium chloride
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Sirius Therapeutics Co., Ltd.
Cardiovascular Diseases, Heart Diseases
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
Coronary heart disease (CHD) is a serious health concern that affects millions of people in the United States. It is usually caused by atherosclerosis-a condition that occurs when fatty material and plaque build up on the walls…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Atherosclerosis
- Trial name
- HDL Proteomics (NCT00880178)
- Testing
- Simvastatin and Extended-Release niacin, Simvastatin
- Where
- 29 sites in United States, Canada
- Volunteers
- 324 people
- Sponsor
- University of Washington
Critical Limb Ischemia
PROMISE International
The objective of this post-market study is to evaluate the safety and effectiveness of the LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization in subjects with critical limb ischemia.
- Trial name
- NCT03321552
- Testing
- Percutaneous deep vein arterialization, LimFlow System
- Where
- 12 sites in Austria, Germany and 3 more
- Volunteers
- 34 people
- Sponsor
- LimFlow SA
Peripheral Artery Disease, Peripheral Vascular Disease
Absolute Pro® MOMENTUM™
To evaluate the safety and effectiveness of the Absolute Pro® Peripheral Self-Expanding Stent System and the Absolute Pro® LL Peripheral Self-Expanding Stent System for the treatment of subjects with atherosclerotic de novo or…
- Trial name
- MOMENTUM (NCT01444378)
- Testing
- Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Abbott Medical Devices
Peripheral Artery Disease
ACOART BTK RENEW：A Post Market Clinical Study
The objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the Acotec Litos\&Tulip Drug-coated Balloon catheters in the treatment of lesions in below-the-knee…
- Trial name
- NCT04885985
- Testing
- DEB catheter
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Acotec Scientific Co., Ltd
Lupus Erythematosus, Systemic
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
The purpose of this study is: 1. To assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of atherosclerosis that predisposes children with SLE to cardiovascular events in adulthood. 2.
- Trial name
- NCT00065806
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Laura Schanberg
Atherosclerosis
Relation of Circulating Endothelium-derived Microparticle to Carotid Atherosclerosis
The investigators hypothesized that circulating endothelium-derived microparticle (EMP) may be a useful surrogate marker of atherosclerosis and future episode of cerebrovascular events.
- Trial name
- NCT00795067
- Where
- Japan
- Volunteers
- 154 people
- Sponsor
- Kurume University
Peripheral Artery Disease
Implementation of Vascular Care Team to Improve Medical Management of PAD Patients
This study intends to evaluate the efficacy of a multidisciplinary vascular care team utilizing an intensive guideline-based lipid reduction program in improving risk factor modification as measured by LDL-C reduction at 12…
- Trial name
- NCT04400409
- Testing
- Intervention A - Vascular Care + site 6MWT administration, Intervention B - Standard Care + site 6MWT administration, Intervention A - Vascular Care + CPC EQuIP 6MWT administration
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- Colorado Prevention Center
Arterial Stiffening, Aging
Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
The purpose of this study is to find out why women's arteries stiffen as they go through menopause, and how this is affected by estrogen loss.
- Conditions
- Arterial Stiffening, Aging, Menopause
- Trial name
- SHAPE (NCT00608062)
- Testing
- GnRHant - Ganirelix acetate, Transdermal estradiol patch
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Stroke, Ischemic, Stroke, Acute
Ischemic Strokes While on NOAC - How Compliance Matters
This study is aimed to depict the epidemiological trend, aetiologies, clinical characteristics, treatment options of IS-NOAC in face of the rapidly increasing NOAC usage.
- Conditions
- Stroke, Ischemic, Stroke, Acute, Stroke Syndrome, Stroke, Cardiovascular
- Trial name
- NCT04607070
- Where
- Hong Kong
- Volunteers
- 91 people
- Sponsor
- Chinese University of Hong Kong
Coronary Artery Disease
Dietary Intervention to Stop COronary Atherosclerosis in Computed Tomography
The aim of the study is to determine, wheather strict dietary intervention with the use of the DASH diet atop of optimal medical treatment reduces previously diagnosed coronary atherosclerotic lesions assessed witch coronary…
- Trial name
- DISCO-CT (NCT02571803)
- Testing
- Dietary And Lifestyle Counseling, Optimal Medical Treatment
- Where
- Poland
- Volunteers
- 180 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Systemic Lupus Erythematosus, Cardiovascular Disease
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.
- Conditions
- Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
- Trial name
- NCT05440422
- Testing
- anifrolumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.